Show source-provided references
3. Turning Ineffective Transplatin into a Highly Potent Anticancer Drug via a Prodrug Strategy for Drug Delivery and Inhibiting Cisplatin Drug Resistance
10.1021/acs.bioconjchem.6b00302 ↗4. Nanoparticle delivery of sterically hindered platinum(IV) prodrugs shows 100 times higher potency than that of cisplatin upon light activation
10.1039/C5CC09534D ↗5. Delivering a photosensitive transplatin prodrug to overcome cisplatin drug resistance
10.1039/C5CC03692E ↗8. Tsvetkova, D., and Ivanova, S. (2022). Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases. Molecules, 27.
10.3390/molecules27082466 ↗9. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473
10.1038/bjc.1998.59 ↗10. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts
11. Peroxidase-like Active Nanomedicine with Dual Glutathione Depletion Property to Restore Oxaliplatin Chemosensitivity and Promote Programmed Cell Death
10.1021/acsnano.1c06777 ↗15. Broadening the clinical use of platinum drug-based chemotherapy with new analogues: Satraplatin and picoplatin
10.1517/13543784.16.7.1009 ↗16. Pt(IV) Prodrugs Designed to Bind Non-Covalently to Human Serum Albumin for Drug Delivery
10.1021/ja5038269 ↗18. Proteomic analysis of cisplatin- and oxaliplatin-induced phosphorylation in proteins bound to Pt-DNA adducts
10.1039/d0mt00194e ↗23. Nanoparticle-based drug delivery systems with platinum drugs for overcoming cancer drug resistance
10.1039/D1TB00753J ↗24. Advances in drug delivery system for platinum agents based combination therapy
30. Role of glutathione in the regulation of Cisplatin resistance in cancer chemotherapy
10.1155/2010/430939 ↗32. Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines
10.1038/sj.bjc.6600786 ↗33. Depletion of GSH in glial cells induces neurotoxicity: Relevance to aging and degenerative neurological diseases
10.1096/fj.09-149997 ↗34. Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR/ABL inhibition, cytotoxic drugs, and gamma-irradiation
10.1038/sj.leu.2402179 ↗35. Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies
10.1023/A:1013156407224 ↗